Login to Your Account

Medicines' Oritavancin Strong In Confirmatory Phase III Trial

By Randy Osborne
Staff Writer

Tuesday, July 2, 2013
Another set of positive Phase III data with oritavancin, a semi-synthetic lipoglycopeptide antibiotic, in acute bacterial skin and skin structure infections puts The Medicines Co. in line for a 2014 approval, and possibly a partnership to help commercialize the compound, which treats disorders caused by susceptible gram-positive bugs that include methicillin-resistant Staphylococcus aureus.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription